AI Drug Discovery Companies: The 2026 Power List

How to Read This List

There are now hundreds of companies that describe themselves as “AI drug discovery.” Most lists rank them by funding, which is the easiest number to find and the least useful one to act on. A billion-dollar launch tells you investors are excited; it tells you nothing about whether the platform produces drugs that work.

We rank by a blend of capital, validation, and clinical progress — weighting real-world signals (repeat pharma partnerships, peer-reviewed clinical data, advancing trials) above raise size. Where a company sits in our three tiers reflects how far it has converted AI promise into evidence, not how much it has raised. This is the view we take when advising clients on which platforms are worth partnering with or sourcing assets from.

Concretely, we weight four inputs: clinical validation (peer-reviewed data and advancing trials carry the most weight); commercial validation (the number and durability of pharma partnerships, with renewals weighted above first deals); platform depth (proprietary data and wet-lab validation loops, not model architecture alone); and capital (necessary, but on its own the weakest signal). A company can lead on funding and still sit a tier lower if the evidence has not caught up — which is exactly the distinction this list exists to draw.

For the market context behind this list — funding flows, deal structures, and the first clinical proof points — start with our AI in Drug Development: The Dealmaker’s Guide.

The 2026 Power List

Disclosed funding figures are approximate, as of October 2026, and drawn from company announcements, filings, and public reporting (see Sources); “approach” is simplified for orientation. All companies are private unless marked public.

Tier 1: The Best-Capitalized Platforms

Isomorphic Labs is the bellwether. Spun out of Google DeepMind and led by Nobel laureate Demis Hassabis, it carries the AlphaFold lineage into commercial drug design. Its 2024–2025 partnerships with Eli Lilly (up to $1.7B in milestones) and Novartis (up to $1.2B), a 2026 collaboration with Johnson & Johnson, and $2.7B from its first two external funding rounds ($600M in 2025 and a $2.1B Series B in May 2026) make it the most validated platform by the only test that counts early — whether Big Pharma will pay for repeated access.

Xaira Therapeutics launched in 2024 with over $1 billion behind protein-design pioneer David Baker and former Genentech CSO Marc Tessier-Lavigne — one of the largest AI-biotech launches to date, but still early in converting capital to pipeline. Generate:Biomedicines (~$805M raised privately and $400M in a February 2026 IPO, with its lead antibody GB-0895 in Phase 3 for severe asthma) and insitro (~$640M, deep pharma collaborations) round out the well-capitalized generative/genomics camp. Recursion, public and fortified by its Exscientia merger and an NVIDIA-built supercomputer, is the most comprehensive platform — but its 2025 pipeline cuts are the clearest reminder that scale alone is not a drug.

Tier 2: The Clinical Provers

Capital gets attention; the clinic gets respect. Insilico Medicine sits here at the top because it delivered the field’s defining proof point: rentosertib, an AI-discovered and AI-designed TNIK inhibitor, posted a positive Phase IIa in idiopathic pulmonary fibrosis, published in Nature Medicine in 2025. Relay Therapeutics (motion-based design), now in Phase 3, and Schrödinger (physics + ML, with a software business and two Phase 1 assets) have long-standing clinical programs. Iambic Therapeutics, which listed on Nasdaq in October 2026, has its HER2 inhibitor IAM1363 in a Phase 1/1b trial and a clinical collaboration with Jazz Pharmaceuticals — a sign pharma is engaging beyond pure platform deals.

The nuance worth holding: Schrödinger is as much a software company as a drug developer — all of the top 20 pharma companies licensed its physics-based platform in 2025, giving it a revenue base most peers lack. It has also said it will finish the Phase 1 trials of its two clinical assets, seek partners for them, and not take further programs into the clinic on its own. Relay bets that modeling protein motion (not just static structure) unlocks harder targets, and its PI3Kα inhibitor zovegalisib is now in a Phase 3 breast cancer trial with FDA Breakthrough Therapy designation. And Iambic’s physics-informed neural networks aim squarely at clinical assets — the HER2 drug IAM1363, the KIF18A inhibitor IAM217 (IND submitted in September 2026), and the CDK2/4 inhibitor IAM-C1 (IND planned for the fourth quarter of 2026) mark the transition from “platform” to “pipeline” that ultimately separates the durable companies from the demos.

Tier 3: The Rising Platforms

Genesis Molecular AI (formerly Genesis Therapeutics; $280M+ raised, a16z-backed) applies graph neural networks to molecular property prediction, and in May 2026 Incyte expanded their collaboration with $120M upfront (including a $40M equity purchase) and more than $1B in potential milestones across five initial targets. Chai Discovery (~$625M raised, including a $400M Series C at a $3.8B valuation in July 2026; OpenAI-backed) is building molecular-structure foundation models (the Chai-1 to Chai-3 line), which Lilly, Pfizer, and Novartis have started adopting, and represents the “AI-first, pipeline-later” bet. These are platform wagers: their value will be set by whether their models translate into partnered or proprietary programs over the next 24 months.

How the Platforms Differ Technically

“AI drug discovery” hides several genuinely different technical bets. Knowing which one a company is making tells you what kind of asset it can produce and where it can fail:

• Structure prediction & design (Isomorphic) — the AlphaFold lineage: predict a protein’s structure, then design molecules against it. Strong for novel targets; depends on structure being the bottleneck.
• Generative protein design (Xaira, Generate) — the David Baker lineage: invent new proteins and binders from scratch. Expands the biologics design space dramatically.
• Phenomics / scaled biology (Recursion) — image millions of cellular states to map biology empirically, then design chemistry against what you observe. Data-rich, compute-heavy.
• Physics-based + ML (Schrödinger, XtalPi, Iambic) — ground predictions in physical simulation, augmented by learning. More interpretable; computationally expensive.
• Graph & foundation models (Genesis, Chai) — learn molecular properties and structure from large datasets. The most “AI-native,” the least clinically proven so far.

Public vs Private Exposure

For investors and corporate-development teams thinking about where to get exposure, the list splits cleanly. Public vehicles include Recursion (Nasdaq: RXRX), Schrödinger (Nasdaq: SDGR), Relay Therapeutics (Nasdaq: RLAY), and — newly — Generate (Nasdaq: GENB), Eikon (Nasdaq: EIKN), and Iambic (Nasdaq: IAM) after their 2026 IPOs, plus the Hong Kong listings of Insilico and XtalPi. Private leaders include Isomorphic Labs (held within Alphabet), Xaira, insitro, Genesis, and Chai.

The practical implication: the best-validated platform on the list (Isomorphic) is not directly investable, while the most directly investable names carry the volatility of clinical-stage biotech. Partnership and asset-sourcing — not equity — remains the primary way most pharma and advisory clients engage the private leaders, which is exactly where deal structuring expertise earns its keep.

The Demand Side: Big Pharma’s Bets

A power list of platforms only tells half the story. The other half is which pharma giants are committing — because their choices are the market’s real validation signal. The pattern in 2025–2026 was a shift from buying single assets to buying capability:

• Eli Lilly is the most aggressive: a partnership with Isomorphic (up to $1.7B in milestones), a generative-AI capability deal with Chai, and an up-to-$1B, five-year AI co-innovation lab with NVIDIA, which builds on the AI supercomputer Lilly announced in 2025.
• Novartis partnered with Isomorphic (up to $1.2B in milestones) and expanded the collaboration in 2025, adding up to three more programs on the same terms — an expansion that signals genuine conviction, not a one-off bet.
• Johnson & Johnson became Isomorphic’s third pharma partner in January 2026, evidence the platform’s validation is broadening.
• Roche/Genentech and Bayer back Recursion (under a December 2021 deal, Roche paid $150M upfront in January 2022 for phenomaps and programs in neuroscience and a gastrointestinal cancer; Bayer refocused its collaboration on precision oncology in 2023), while GSK took a subscription-style licensing deal with Noetik.

For a buyer or an asset-holder, this matters: a platform that several top-ten pharmas have independently chosen carries validation that no funding round can buy. The full deal terms sit in our AI Drug Discovery Deal Tracker.

The China Subset

The most underappreciated fact on this list: two of its most consequential names are China-rooted. Insilico Medicine (Hong Kong/China, ~$293M HKEX IPO in December 2025) produced the field’s clinical proof point, and XtalPi (Chinese, HKEX-listed, about $1.6B raised including its IPO and 2025 placements) pairs quantum-physics simulation with AI at scale. The structural edge is the same one driving the broader China out-licensing wave: generative design plus fast, lower-cost clinical execution.

For cross-border dealmakers, AI-originated Chinese assets are among the best risk-adjusted entries into the category — they reach human proof-of-concept faster and become out-licensing candidates for global pharma. We cover this in depth in Top Chinese Biotech Companies and the China outbound licensing tracker.

The signal is hard to overstate: the company that produced the field’s first peer-reviewed Phase II proof point was not a Boston or Bay Area platform but a Hong Kong/China-rooted one. Insilico’s Pharma.AI engine spans target discovery through generative chemistry, and its pipeline extends well beyond rentosertib into oncology and fibrosis. XtalPi, meanwhile, has built one of the largest combined quantum-physics-and-AI computational operations in the industry and monetizes it through both partnerships and an emerging pipeline. Together they make the case that the center of gravity in AI drug discovery is no longer exclusively American.

How This List Will Change

A power list is a snapshot of a fast-moving field. Four forces will reshuffle it over the next 12–24 months, and each is worth watching:

• Clinical readouts. The single biggest mover. Recursion’s next readouts (more REC-4881 Phase 2 data in November 2026, then early Phase 1 data across its oncology programs through 2027), follow-on data for Insilico’s rentosertib, Phase 3 results from Relay and Generate, and the first clinical data from Xaira and other newer protein-design platforms will promote or demote names faster than any raise.
• Partnership renewals — and failures. Another Isomorphic-style expansion validates a platform; a quietly terminated collaboration is a warning the market often misses.
• Consolidation. The Recursion–Exscientia merger will not be the last. Expect platform-on-platform M&A and acqui-hires as capital tightens around the validated few.
• The China ascent. If more AI-originated Chinese assets reach proof-of-concept and out-license to global pharma, the list’s center of gravity keeps shifting east.

We revise this ranking as those events land. The constant is the scoring logic: validation over valuation, evidence over narrative.

Frequently Asked Questions

A Dealmaker’s Read

If you are evaluating a partnership or an in-licensing opportunity from any company on this list, weight the signals in this order:

• Repeat pharma partnerships — especially renewals and expansions — are the strongest external validation. One large deal can be a bet; two is a pattern.
• Peer-reviewed clinical data beats any platform demo. Insilico’s Nature Medicine paper is worth more than a billion-dollar Series A.
• Pipeline discipline — a company that cuts weak programs (as Recursion did) is often healthier than one that claims everything is working.
• Origin matters — China-rooted platforms can offer faster, cheaper proof-of-concept and cleaner out-licensing entry points.

And the red flags that should slow a deal down:

• “Validated” by funding alone. A nine-figure round with no pharma partner and no clinical data is investor conviction, not scientific validation.
• Vague probability-of-success claims. If a platform cannot articulate why it improves the odds of approval — beyond speed — assume it improves speed only.
• Opaque IP or data provenance. Unclear human inventorship or training-data rights is a latent liability on any AI-originated asset.

The full how-to on valuing and structuring these deals — discounting biobucks, demanding a probability-of-success thesis — is in the dealmaker’s guide, and live comparables sit in the licensing deal tracker.

Vision Lifesciences helps clients source, diligence, and structure partnerships with platforms like these — including cross-border AI-originated assets. Talk to our team about a specific opportunity.

Sources

1. Vision Lifesciences research: our own deal tracking and insights from our day-to-day cross-border licensing and M&A advisory work (about us)
2. Isomorphic Labs, Series B investment round of $2.1 billion (May 2026)
3. Isomorphic Labs, research collaboration with Johnson & Johnson (January 2026)
4. Isomorphic Labs, Novartis collaboration expansion (February 2025)
5. pharmaphorum, Isomorphic signs up Lilly, Novartis for $3bn AI drug hunt (January 2024)
6. Isomorphic Labs, $600m external investment round (March 2025)
7. Insilico Medicine, Nature Medicine publication of Phase IIa results for rentosertib (June 2025)
8. Law.asia, Firms advise on Insilico Medicine’s HKD2.28bn HKEX IPO (January 2026; IPO December 2025)
9. Recursion, second quarter 2026 results and pipeline milestones (August 2026)
10. Recursion, 2022 annual report (Roche and Genentech collaboration terms)
11. Bayer, Bayer and Recursion focus research collaboration on oncology (November 2023)
12. Xaira Therapeutics, launch with more than $1 billion in committed capital (April 2024)
13. Generate:Biomedicines, registration statement (private funding and GB-0895 Phase 3 program, February 2026)
14. Generate:Biomedicines, IPO prospectus (February 2026)
15. Eikon Therapeutics, IPO prospectus (February 2026)
16. Schrödinger, 2025 annual report (software customers and clinical strategy)
17. Relay Therapeutics, zovegalisib data at the Phase 3 dose and ReDiscover-2 trial (March 2026)
18. Iambic, pricing of initial public offering (October 2026)
19. Iambic Therapeutics, IPO prospectus (funding to date and pipeline, October 2026)
20. BiopharmaTrend, XtalPi begins trading on the Hong Kong Stock Exchange (June 2024)
21. Sidley, XtalPi’s third placing of new shares (September 2025)
22. Forbes Argentina, XtalPi pre-IPO funding (Frost & Sullivan figure, December 2023; in Spanish)
23. Pharmaceutical Technology, Genesis Therapeutics wins $200m in Series B round, total funding over $280m (August 2023)
24. Genesis Molecular AI, Incyte and Genesis expand collaboration (May 2026)
25. Chai Discovery, Series C of $400 million (July 2026)
26. TechCrunch, Chai Discovery raises $130M Series B (December 2025)
27. NVIDIA, NVIDIA and Lilly announce co-innovation AI lab (January 2026)
28. Noetik, GSK licenses Noetik’s AI foundation models (January 2026)
29. Jayatunga et al., How successful are AI-discovered drugs in clinical trials? A first analysis and emerging lessons, Drug Discovery Today (2024)
30. DealForma, AI-ML drug discovery and licensing: R&D, M&A, ventures and IPOs, 2025 review (January 2026)